Futura's topical anti-inflammatory effective in skin studies

By Lisa Kerner

Charlotte, N.C., Sept. 6 - Futura Medical plc said its new topical non-steroidal anti-inflammatory (Nsaid) formulation, DCF100, had permeation rates eight times that of Voltarol Emulgel in recently conducted in vitro human skin studies.

DCF100 also showed a statistically significant improvement in drug delivered in a 24-hour period from a single dose compared with Pennsaid, a prescription based topical Nsaid.

The company plans to conduct human tissue micro-dialysis and plasma-level studies of DCF100 later this year.

Futura is a Guildford, England-based pharmaceutical and medical device company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.